HealthcareServices

Corneal Endothelial Dystrophy Market to Grow at a CAGR of 7.9% from 2025 to 2029

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Corneal Endothelial Dystrophy Market Covering 2025–2034?

The market for corneal endothelial dystrophy has experienced robust expansion in recent years. It is projected to increase from $170.96 billion in 2024 to $184.84 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.1%. The growth observed in previous periods is largely due to factors such as rising healthcare expenditures, an increased occurrence of endothelial corneal dystrophy, an expanding aging population, a growing prevalence of various eye diseases, and a significant rise in corneal disorders.

The market for corneal endothelial dystrophy is projected to experience substantial expansion in the coming years. This market is anticipated to reach $250.98 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.9%. Several factors contribute to this growth over the forecast period, including an increase in corneal blindness in developing nations, greater awareness regarding eye health, a rising need for corneal transplantation, improvements in healthcare infrastructure, and a growing incidence of chronic conditions. Key trends anticipated during this period encompass developments in regenerative treatments, progress in medical technology, enhancements in diagnostic methodologies, technological leaps in ophthalmic lasers, and other advanced technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21158&type=smp

What Are The Drivers Pushing New Developments In The Corneal Endothelial Dystrophy Market?

The expansion of the corneal endothelial dystrophy market is anticipated to be propelled by the increasing need for corneal transplantation going forward. This procedure involves surgically replacing a compromised or unhealthy cornea with a healthy donor cornea, aiming to restore sight and enhance ocular well-being. The escalating demand for these transplantations stems from a higher incidence of corneal conditions, continuous progress in surgical methodologies, and better rates of organ donation. Corneal endothelial dystrophy is managed through corneal transplantation, where the impaired endothelium is supplanted by healthy donor tissue, leading to restored corneal transparency, decreased swelling, and enhanced visual acuity. For example, data from the Eye Bank Association of America, a US-based transplant organization, indicates that domestic keratoplasty (a type of corneal transplantation) procedures saw an increase of 2.7% in 2023, climbing from 49,597 in 2022 to 50,925 in 2023. Consequently, the increasing need for corneal transplantation is fueling the expansion of the corneal endothelial dystrophy market.

What Are The Major Segment Categories Driving The Corneal Endothelial Dystrophy Market Growth?

The corneal endothelial dystrophymarket covered in this report is segmented –

1) By Treatment: Phototherapeutic Keratectomy; Amniotic Membrane Transplants; Anterior Stromal Puncture; Conjunctival Flaps

2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1; Congenital Hereditary Endothelial Dystrophy 2; Posterior Polymorphous Corneal Dystrophy; Fuchs Endothelial Corneal Dystrophy

3) By Diagnosis: Cornea Examination And Grading; Corneal Tomography; Corneal Pachymetry; Corneal Cell Count

4) By End-User: Hospitals; Clinics; Other End Users

Subsegments:

1) By Phototherapeutic Keratectomy: Excimer Laser Therapy; Corneal Reshaping

2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant; Cryopreserved Amniotic Membrane Transplant

3) By Anterior Stromal Puncture: Manual Technique; Laser-Assisted Technique

4) By Conjunctival Flaps: Partial Flap Technique; Full Flap Technique

What Trends Are Redefining The Corneal Endothelial Dystrophy Market Dynamics?

Major companies operating in the corneal endothelial dystrophy market are focusing on developing innovative treatments, such as allogeneic cell therapy, to address unmet medical needs by offering pioneering, minimally invasive treatment options that improve patient outcomes. Allogeneic cell therapy involves using cells from a donor of the same species but genetically distinct to treat a recipient. For instance, in September 2024, Aurion Biotech Inc., a US-based clinical-stage biotech company, launched Vyznova (neltependocel) in Japan to treat bullous keratopathy, a corneal endothelial disease. Vyznova (neltependocel) is a cell therapy developed by Aurion Biotech to address bullous keratopathy, which damages corneal endothelial cells and causes vision problems. It is the first approved cell therapy for corneal endothelial disease and has received approval in Japan. Vyznova utilizes corneal endothelial cells grown in a lab, enabling up to 1,000 doses to be produced from a single donor. This innovative treatment offers a less invasive alternative to corneal transplants, helping to alleviate the shortage of donor corneas and providing a new method to restore vision for patients with corneal diseases.

Who Are The Primary Competitors In The Global Corneal Endothelial Dystrophy Market?

Major companies operating in the corneal endothelial dystrophy market are F. Hoffmann-La Roche AG, Abbvie (Allergan plc), Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, Emmecell S.R.L

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/corneal-endothelial-dystrophy-global-market-report

What Regional Growth Trends Are Shaping The Corneal Endothelial Dystrophy Market Outlook?

North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Corneal Endothelial Dystrophy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21158&type=smp

Browse Through More Reports Similar to the Global Corneal Endothelial Dystrophy Market 2025, By The Business Research Company

Corneal Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/corneal-implants-global-market-report

Vascular Endothelial Growth Factor Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Anti Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795